Incyte amps up in Europe with $140M-plus Ariad deal

Incyte may have shelled out to license Ariad Pharmaceuticals’ leukemia therapy Iclusig in Europe, but the drug isn’t the crux of the deal. Incyte, revving up its pipeline of drug candidates, also wants to get its hands on Ariad’s commercial infrastructure on the continent.